RxDoctor Payments Data

Uzma Rahat, MD

Geriatric Medicine · West Columbia, TXNPI 1811180235

Payments from drug & device makers

$348in general payments, 2019–2025

Across 12 payments — averaging $29.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$142
  • AstraZeneca$87
  • Exact Sciences$30
  • Calliditas Therapeutics US Inc.$26
  • Corcept Therapeutics$25
  • Kowa Pharmaceuticals America, Inc.$23
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$348 in reported general payments places this provider in the 60th percentile of 275 geriatric medicine providers in Texas.

See all geriatric medicine providers in Texas

Medicare billing

Part B allowed, 2024
$55,524
Medicare patients
218
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$92,012
FarxigaDapagliflozin Propanediol37$38,970
JanuviaSitagliptin Phosphate18$11,557
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,441
Atorvastatin Calcium113$1,125
Albuterol Sulfate HfaAlbuterol Sulfate35$959
Rosuvastatin Calcium34$871
Wixela InhubFluticasone Propion/Salmeterol13$608
Amlodipine Besylate99$597
Gabapentin59$579
Levothyroxine Sodium47$519
Losartan Potassium40$512
Tamsulosin Hcl16$500
Ezetimibe18$468
Allopurinol34$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$92,01271 claims
AstraZenecaFarxiga$87$38,97037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 275 geriatric medicine providers in Texas.

Other geriatric medicine in West Columbia

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →